1. Updates for Dermatologists and Rheumatologists on PsA Management: Role of IL-17 Inhibitors

2. IL-17 Inhibitors in the Management of Psoriatic Disease

3. Agenda

4. Treat-to-Target in PsA

5. Early Intervention and Tight Control of Inflammation in Patients With PsA: TICOPA

6. MDA Criteria

7. TICOPA: Commonly Reported AEs

8. Key Domains of PsA

9. Clinical Challenges to Meeting Treatment Goals in PsA

10. GRAPPA Treatment Schema for Active PsA

11. National Psoriasis Foundation: Treatment Targets for Plaque Psoriasis

12. Overlap of Symptoms in Patients With Psoriatic Disease

13. Treatment Guidelines and Outcomes for PsA

14. Evidence-Based Guidelines for the Management of Patients With PsA

15. Management of Patients With PsA: Domain Involvement Drives Treatment Decisions

16. Multiple Evidence-Based Guidelines for the Management of Patients With Psoriasis Exist

17. Incorporating Evidence-Based Guidelines Into Practice: Clinical Challenges

18. Psoriasis and PsA: Different Manifestations of the Same Disease?

19. PsA Screening Tools

20. Multidisciplinary Dermatology-Rheumatology Management of Patients With Psoriasis and PsA

21. Treatment Considerations for Patients With PsA and Concomitant Comorbidities

22. PsA Treatment

23. Clinical Assessments in Patients With Psoriasis

24. Current and Emerging Biologic Therapy for PsA

25. Available Biologic Therapy for the Treatment of PsA

26. Treatment of PsA With IL-17 Inhibitors

27. Other IL-17 Inhibitors

28. Anti-IL-23 Agents for the Treatment of PsA

29. GRAPPA Guidelines: Treatment According to Domain Involvement

30. GRAPPA Guidelines: Treatment According to Domain Involvement (Cont.)

31. Multidisciplinary Management of Patients With PsA

32. Clinical Challenges in the Management of Patients With PsA

33. Depression in Patients With PsA

34. Brodalumab

35. Symptoms of Depression Improve With Appropriate Treatment of Psoriasis

36. Treatment of PsA and Its Psychosocial Burden

37. CVD in Patients With PsA

38. PsA Treatments and the Effect on CV Outcomes

39. Screen and Manage Modifiable CV Risk Factors to Reduce the Risk for CVD in Patients With PsA

40. Biological Drugs Used in Psoriasis and PsA During Pregnancy

41. Secukinumab in Pregnancy: Outcomes From the Global Safety Database

42. PsA Disease Activity During Pregnancy and the First-Year Postpartum

43. Program Summary

44. Program Summary (Cont.)

45. Abbreviations

46. Abbreviations (cont)

47. Abbreviations (cont)